# A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Source: https://onco.cc/trials/nct04325828/  
OnCo record `nct04325828` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Apalutamide in salivary gland cancers, run by Janssen Pharmaceutical K.K., active and no longer recruiting.

## Summary

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma is a phase 2 interventional study registered as NCT04325828 by Janssen Pharmaceutical K.K., with 31 participants enrolled, started 2020-04-07 and due to reach its primary completion in 2021-06-09. Interventions recorded: Apalutamide and GnRH Agonist. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04325828
- Phase: 2
- Setting: An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma
- Sponsor: Janssen Pharmaceutical K.K.
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT04325828: https://clinicaltrials.gov/study/NCT04325828

## Connected records

- cancers: [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/)

---
JSON: https://onco.cc/api/v1/entities/nct04325828.json